Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372744 | 0.86 | MAPT (0.60) | HNF4ASLC6A3SLC6A4MAPTTSHR | |
| SCHEMBL27843639 | 0.85 | SLC6A3 (0.74) | SLC6A3SLC6A4MAPTTSHRLMNA | |
| SCHEMBL1775832 | 0.85 | SLC6A3 (0.74) | SLC6A3SLC6A4MAPTTSHRLMNA | |
| SCHEMBL23358783 | 0.84 | HNF4A (0.68) | HNF4ASLC6A3SLC6A4MAPTTSHR | |
| Phosphine SCHEMBL11469830 | 0.84 | SLC6A3 (0.72) | SLC6A3SLC6A4MAPTTSHRLMNA | |
| Bicarbonate SCHEMBL27467504 | 0.84 | SLC6A3 (0.72) | SLC6A3SLC6A4MAPTTSHRLMNA | |
| SCHEMBL7893798 | 0.84 | SLC6A3 (0.48) | HNF4ASLC6A3SLC6A4MAPTMITF | |
| SCHEMBL27673670 | 0.83 | HNF4A (0.62) | HNF4ASLC6A3SLC6A4MAPTMITF | |
| SCHEMBL28409137 | 0.83 | GAA (0.50) | HNF4ASLC6A3SLC6A4MAPTMITF | |
| SCHEMBL28414807 | 0.83 | SLC6A3 (0.52) | HNF4ASLC6A3SLC6A4MAPTMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| CN-1178932-C | Amide derivatives | — | 2004-12-08 | — | — | CN | disclosed |
| US-6417178-B1 | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits | UNIVERSITY OF PITTSBURGH | 2002-07-09 | — | — | US | disclosed |
| CN-1350530-A | Amide derivatives | ASTRAZENECA AB (SE) | 2002-05-22 | — | — | CN | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-1999024394-A9 | COMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIV PITTSBURGH (US) | 2001-05-31 | — | — | WO | disclosed |
| US-5965741-A | ANTIINFLAMMATORY, ANTIPYRETIC AND ANTIDIARRHOEAL PROPERTIES | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| WO-1999024394-A2 | COMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0778821-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996006822-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1996-03-07 | — | — | WO | disclosed |
| EP-0221346-B1 | (N-SUBSTITUTED-2-HYDROXY) BENZAMIDES AND N-SUBSTITUTED-2-HYDROXY-ALPHA-OXO-BENZENEACETAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF HAVING ACTIVITY AS MODULATORS OF THE ARACHIDONIC ACID CASCADE | WARNER-LAMBERT COMPANY (US) | 1991-01-30 | — | — | EP | disclosed |
| US-4939133-A | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0221346-A1 | (N-substituted-2-hydroxy) benzamides and N-substituted-2-hydroxy-alpha-oxo-benzeneacetamides and pharmaceutical compositions thereof having activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
| US-4116961-A | ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4024160-A | Substituted 2-amino chromones and process for the preparation thereof | WARNER-LAMBERT COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
| US-3932466-A | Substituted 2-amino chromones and process for the preparation thereof | WARNER-LAMBERT COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | HNF4A 170/4885SLC6A3 2883/4885SLC6A4 2919/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | HNF4A 170/4885SLC6A3 2883/4885SLC6A4 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.